Anticancer drug-containing plant virus particles
OwnerNicole F. Steinmetz, Stephen Lippard +2inventors
InventorsNicole F. Steinmetz, Stephen Lippard, Anna Czapar, Yaorong Zheng
Life of this patent
Estimating the term…
Abstract
Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.
Claims18
1:
- An anticancer virus particle, comprising a cowpea mosaic virus (CPMV) virus particle and a cationic platinum-based anticancer agent covalently conjugated to an interior cavity of the virus particle.
2-7. (canceled)
8:
- The anticancer virus particle of claim 1, wherein the exterior surface of the CPMV virus particle has been PEGylated.
9-10. (canceled)
11:
- The anticancer virus particle of claim 1, wherein the cationic platinum-based anticancer agent is phenanthriplatin.
12-13. (canceled)
14:
- The anticancer virus particle of claim 1, wherein a targeting ligand is attached to the exterior of the CPMV virus particle.
15:
- A method of treating cancer in a subject identified as having cancer by administering to the subject a therapeutically effective amount of an anticancer virus particle, comprising a cowpea mosaic virus (CPMV) virus particle and a cationic platinum-based anticancer agent covalently conjugated to an interior cavity of the CPMV virus particle.
16:
- The method of claim 15, wherein the cancer is ovarian cancer, colon cancer, brain cancer, or breast cancer.
17:
- The method of claim 15, wherein the anticancer virus particle is administered together with a pharmaceutically acceptable carrier.
18-19. (canceled)
20:
- The method of claim 15, wherein the exterior surface of the CPMV virus particle has been PEGylated.
21-23. (canceled)
24:
- The method of claim 21, wherein the cationic platinum-based anticancer agent is phenanthriplatin.
(canceled)
26:
- The method of claim 15, wherein a targeting ligand is attached to the exterior of the CPMV virus particle.
27:
- The method of claim 1, wherein the cationic platinum-based anticancer agent is covalently conjugated to a thiol group in the interior cavity of the virus particle.
28:
- The method of claim 15, wherein the cationic platinum-based anticancer agent is covalently conjugated to a thiol group in the interior cavity of the virus particle.
Dependencies are inferred from the claim text.